CMV Therapeutics

Prevention of symptomatic and potential life-threatening infection by accurate early-stage diagnosis plus timely intervention is the best therapeutic approach for treating EBV/CMV infections in patients with immature or defective immune responses.

RNA and DNA approach

Cyto-Barr has created unique reagents for serodiagnostic applications and explored innovative DNA and RNA based approaches for early-stage molecular diagnosis, prevention and therapeutic monitoring of life-threatening virus infections in transplant recipients, HIV/AIDS patients and other immunocompromised patients.
Multiple published (inter)national studies have shown the usefulness of our approaches.

In recent studies our reagents were instrumental for early-life detection EBV infection in children in African regions with high risk for Burkitt Lymphoma (BL), and are currently evaluated in BL-treatment studies.